Literature DB >> 688279

Plasma levels and urinary excretion of filterable platinum species following bolus injection and iv infusion of cis-dichlorodiammineplatinum(II) in man.

T F Patton, K J Himmelstein, R Belt, S J Bannister, L A Sternson, A J Repta.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 688279

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  35 in total

1.  In vitro colony inhibition of carboplatin against stomach and lung cancer cell lines in comparison with cisplatin.

Authors:  H Takahashi; Y Sasaki; N Saijo; M Sakurai; H Nakano; K Nakagawa; A Hoshi; J R Jett; W S Hong
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

2.  In vitro evaluation of anticancer drugs in relation to development of drug resistance in the human tumor clonogenic assay.

Authors:  K Inoue; T Mukaiyama; I Mitsui; M Ogawa
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

3.  In vitro plasma binding of some second generation antitumor platinum complexes.

Authors:  R Momburg; M Bourdeaux; M Sarrazin; F Roux; C Briand
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Jan-Mar       Impact factor: 2.441

4.  Chemosensitivity of malignant human brain tumors. Preliminary results.

Authors:  U Bogdahn
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

5.  Therapeutic efficacy and pharmacokinetics of vindesine and vindesine-cisplatin in previously treated patients with non-small cell lung carcinoma.

Authors:  J Z Fuks; M J Egorin; J Aisner; D A Van Echo; S Ostrow; N R Bachur; P H Wiernik
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

6.  Pharmacokinetic study of cerebrospinal fluid penetration of cis-diamminedichloroplatinum (II).

Authors:  P E Gormley; D Gangji; J H Wood; D G Poplack
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

Review 7.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

8.  Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion.

Authors:  J J Gullo; C L Litterst; P J Maguire; B I Sikic; D F Hoth; P V Woolley
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

9.  Pharmacokinetics of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum IV (CHIP) in patients with advanced cancer.

Authors:  L Pendyala; W Greco; J W Cowens; S Madajewicz; P J Creaven
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

10.  Disposition of total and free cisplatin on two consecutive treatment cycles in patients with ovarian cancer.

Authors:  C Erlichman; S J Soldin; J J Thiessen; J F Sturgeon; S Fine
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.